| [September 05, 2017] |
 |
Alnylam to Webcast Presentation at 15th Annual Morgan Stanley Global Healthcare Conference
Alnylam
Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics
company, today announced that management will present a company overview
at the 15th Annual Morgan Stanley Global Healthcare
Conference on Wednesday, September 13, 2017 at 9:55 am ET at the Grand
Hyatt in New York City.
A live audio webcast of the presentation will be available on the
Investors section of the company's website, www.alnylam.com.
A replay will be available on the Alnylam website within 48 hours after
the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the lives
of patients who have limited or inadequate treatment options. Based on
Nobel (News - Alert) Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
debilitating diseases. Founded in 2002, Alnylam is delivering on a bold
vision to turn scientific possibility into reality, with a robust
discovery platform and deep pipeline of investigational medicines,
including three product candidates that are in late-stage development or
will be in 2017. Looking forward, Alnylam will continue to execute on
its "Alnylam 2020" strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable pipeline
of RNAi-based medicines. For more information about our people, science
and pipeline, please visit www.alnylam.com
and engage with us on Twitter (News - Alert) at @Alnylam.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905006287/en/
[ Back To TMCnet.com's Homepage ]
|
